Genomic diversity of colorectal cancer: Changing landscape and emerging targets

doi:10.3748/wjg.v22.i25.5668

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7847)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

706

WORD

300

HTML

4057

Figures (1-1)

179

Tables (1-3)

164

Sum=5406

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

453

Download

404

Sum=857

Publishing Process of This Article

Item

Count

Browse

758

Download

826

Sum=1584

Jul 7, 2016 (publication date) through Jul 4, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 7, 2016; 22(25): 5668-5677
Published online Jul 7, 2016. doi: 10.3748/wjg.v22.i25.5668

Table 2 Tumor genomic variants and potential targeted therapies of interest

Gene	Agents of Interest	Mechanism of action	Phase	Trial number¹	Comment
FGFR (FGFR1, FGFR2, FGFR3, FGFR4)	Ponatinib	Multi-kinase small molecule inhibitor	II	NCT02272998
	BGJ398	Pan FGFR small molecule inhibitor	I	NCT01928459
RET	Cabozantinib	Multi-kinase small molecule inhibitor	I	NCT02008383	Cabozantinib + panitumumab
	Vandetanib	Multi-kinase small molecule inhibitor	I	NCT01582191
	Apatinib	Multi-kinase small molecule inhibitor
	Ponatinib	Multi-kinase small molecule inhibitor	II	NCT02272998
	RXDX-105	RET and BRAF small molecule inhibtor	I	NCT01877811
	Sunitinib	Multi-kinase small molecule inhibitor
	Sorafenib	Multi-kinase small molecule inhibitor	I	NCT01531361

HER-2	AZD8931	Small molecule inhibitor of EGFR, HER-2, HER-3	I/II	NCT01862003	AZD8931 + FOLFIRI
	Neratinib	Small molecule inhibitor of EGFR, HER-2, HER-3	II	NCT01953926
	HER-2 vaccine	B cell peptide vaccine	I	NCT01376505
	T-DM1	Antibody-drug conjugate of traztuzumab and DM1	II	HERACLES-RESCUE	At the time of traztumab failure
	Pertuzumab	Anti HER-2 monoclonal antibody	II	HERACLES	Pertuzumab + trastuzumab
	Lapatinib	Anti HER-2 small molecule inhibitor	II	HERACLES	Lapatinib + trastuzumab
c-MET (MET, HGFR)	Crizotinib	Multi-kinase small molecule inhibitor		NCT02510001	Crizotinib + PD-0325901
	Tivantinib	c-MET inhibitor		NCT01892527	Tivantinib + cetuximab
	Cabozantinib	c-MET and VEGFR2 inhibitor
	INC280	Small molecule inhibitor of c-MET	II	NCT2205398	INC280 + cetuximab
	AMG102	HGF inhibitor
	AV299	HGF inhibitor

¹Utilizing the NCT number, clinical trial information can be obtained at https://clinicaltrials.gov. FGFR: Fibroblast growth factor receptor; EGFR: Epidermal growth factor receptor; BRAF: v-Raf murine sarcoma viral oncogene homolog B; HER-2: Human growth factor receptor 2; HGFR: Hepatocyte growth factor receptor; TDM-1: Ado-trastuzumab emtansine; VEGFR: Vascular endothelial growth factor receptor.

Citation: Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016; 22(25): 5668-5677
URL: https://www.wjgnet.com/1007-9327/full/v22/i25/5668.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i25.5668